PCSK9 and Familial prostate cancer: These results propose a broad biosafety margin for the PCSK9 axis-targeting PsA as a prostate cancer recurrence suppressor, with hepatocyte cell death observed only at 50-fold the recommended anticancer therapeutic dose [11,23].